Literature DB >> 7428331

Radioimmunoassay for fluphenazine in human plasma.

K K Midha, J K Cooper, J W Hubbard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7428331

Source DB:  PubMed          Journal:  Commun Psychopharmacol        ISSN: 0145-5699


× No keyword cloud information.
  7 in total

Review 1.  Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.

Authors:  S R Marder; J W Hubbard; T Van Putten; K K Midha
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.

Authors:  S R Marder; E M Hawes; T Van Putten; J W Hubbard; G McKay; J Mintz; P R May; K K Midha
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.

Authors:  K K Midha; J W Hubbard; S R Marder; E M Hawes; T Van Putten; G McKay; P R May
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Kinetics of oral fluphenazine disposition in humans by GC-MS.

Authors:  K K Midha; G McKay; R Edom; E D Korchinski; E M Hawes; K Hall
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

Review 6.  Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Authors:  K K Midha; J W Hubbard; S R Marder; B D Marshall; T Van Putten
Journal:  J Psychiatry Neurosci       Date:  1994-07       Impact factor: 6.186

7.  Radioimmunoassay for trifluoperazine in human plasma.

Authors:  K K Midha; J W Hubbard; J K Cooper; E M Hawes; S Fournier; P Yeung
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.